Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Yamo Pharmaceuticals Reports Positive Data from Phase 2 Study of L1-79 in Autism
Details : L1-79 is a tyrosine hydroxylase inhibitor expected to modulate the catecholaminergic pathways, and thereby improve the core autism spectrum disorder symptoms.
Brand Name : L1-79
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 30, 2024
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : L1-79 (DL-alpha-Methyltyrosine) is a tyrosine hydroxylase inhibitor which is under phase 2 clinical development . It is designed to improve the core socialization and communication symptoms of autism spectrum disorder (ASD).
Brand Name : L1-79
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2023
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : The Autism Impact Fund
Deal Size : Undisclosed
Deal Type : Financing
Details : As part of investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD. L1-79, the company’s lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in ASD.
Brand Name : L1-79
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 10, 2021
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : The Autism Impact Fund
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?